[TED]Scott Galloway : How Amazon, Apple, Facebook and Google manipulate our emotions

發表於 政治觀察, 歷史軼聞, 社會經濟 | 發表迴響

數字台灣HD182 19大後習近平的強國之路 謝金河 張五岳 范疇

發表於 政治觀察, 社會經濟 | 發表迴響

《老謝看世界》 2017-11-18 後葉倫時代新貨幣政策 Fed「前瞻」恐陷迷霧 – 專訪邱志昌、吳嘉隆

發表於 政治觀察, 社會經濟 | 發表迴響

11/20生技產業新聞

繼續閱讀

發表於 產業訊息 | 發表迴響

《中國正在說》之—張維為「中國:一個文明型國家的崛起」

  •  中時電子報 復旦大學中國研究院院長張維為

「講好中國故事,發出中國聲音」的東南衛視《中國正在說》節目,本集由鄭若麟擔任主持人,邀請到的嘉賓為復旦大學中國研究院院長張維為,以《中國:一個文明型國家的崛起》為題發表演講。

繼續閱讀

發表於 政治觀察, 社會經濟 | 發表迴響

THANKSGIVING EVERY DAY


Giving thanks to God every day motivates us to look for God’s purpose in everything. In this sermon, Dr. Stanley reflects on the apostle Paul’s instructions to give thanks in every circumstance, without exception (1 Thess. 5:12-18).

發表於 歷史軼聞, 社會經濟 | 發表迴響

聖經鳥瞰39 彼得前後書(三)(王生台弟兄)

發表於 歷史軼聞, 社會經濟 | 發表迴響

11/17生技產業新聞

繼續閱讀

發表於 產業訊息 | 發表迴響

聯生藥愛滋病抗體新藥UB-421之多國多中心三期臨床試驗已完成台灣、中國與泰國地區之申請

聯生藥今日(6471)宣布,其治療愛滋病單株抗體新藥UB-421規劃在台灣、中國與泰國三個地區執行之多國多中心三期臨床試驗,目前除已獲台灣衛福部核准,並已完成中國與泰國地區之申請。

全球目前有近3700萬人的HIV感染患者,約有1950萬人正在使用HAART療法,其中穩定接受HAART療法之病患為UB-421本次三期臨床試驗的目標族群。本次三期臨床試驗為開放式的隨機分配試驗,受試者為穩定接受雞尾酒療法之愛滋病患,改以UB-421單一藥物取代原本抗愛滋病毒療法,療程設計為兩週施打一次UB-421,為期26週,劑量為25mg/Kg,分為兩組,一組持續使用HAART,一組施打UB-421單一藥物。施打26週後,持續追蹤22週。

根據國際市場調查報告指出,臨床醫師改變愛滋病患用藥的主要原因為許多病患傾向更為簡便的用藥方式,其次是抗反轉錄病毒藥物的毒性與副作用太大,影響病患生活品質,再者是抗藥性問題。相較於必須每日服用抗愛滋藥物,愛滋病患更願意嘗試使用每週一次或每月一次且副作用較低的藥物。未來UB-421若能證實兩週施打一次UB-421可取代雞尾酒療法,將可提供病患一個簡便有效的新療法。

繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

[TED] Nicole Avena : How sugar affects the brain

發表於 社會經濟 | 發表迴響

數字台灣HD181FinTech金流革命來了 謝金河 鄭貞茂 劉奕成

發表於 政治觀察, 社會經濟 | 發表迴響

United BioPharma Filed IND to Taiwan, China and Thailand FDA for UB-421 Phase III HAART Substitution Study

United BioPharma (UBP, 6471) announced that the company recently received the approval from Taiwan FDA an IND (Investigational New Drug) application for a multi-nation, multi-center, Phase III clinical trial with UB-421 monotherapy as HAART substitution in HIV infected patients.  The subsequent filing of IND to China and Thailand has also been completed.

According to WHO, there are approximately 37 million people infected with HIV around the world currently. Among them, about 19.5 million persons are using highly active antiretroviral therapy (HAART) and those who are stably taking HAART to control the blood HIV at the undetectable level are the target population of this trial. The phase III trial is a randomized, open-label, controlled trial to investigate the efficacy and safety of UB-421 monotherapy as substitution for stable antiretroviral therapy in HIV-infected adults. Subjects will receive UB-421 by intravenous infusion at 25mg/Kg, bi-weekly for a treatment period of 26 weeks. The subjects will be grouped into tow cohorts, one cohort will continue the original HAART treatment alone and the other cohort will switch to receive UB-421 as the monotherapy for 26 weeks. After the treatment period, subjects in both cohorts will return to HAART and followed for another 22 weeks.

According to the market report, the main reason that the clinicians switch anti-HIV drugs for patients is that most patients prefer simpler and less frequent treatment regimens. In addition, the current anti-retroviral therapy some with serious side effects affects patient’s quality of life greatly. Furthermore, the drug resistance to HAART is also a common problem.

Compared to the current HAART in which the patients need to take medicines daily for a life time, many patients are willing to try novel anti-HIV drugs that only need to be taken weekly or monthly and with milder side effects. If bi-weekly UB-421 monotherapy are clinically proven to replace HAART, it is for sure a simpler and more favorable therapy to the HIV patients.

繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

《老謝看世界》 2017-11-11 全球景氣沒有烏雲 台股站穩萬點多頭續航 – 專訪 呂宗耀

發表於 政治觀察, 社會經濟 | 發表迴響

11/14生技產業新聞

繼續閱讀

發表於 產業訊息 | 發表迴響

伊禮智:5個小妙招,小家變得又大又舒適!

發表於 社會經濟 | 發表迴響